JP2014521675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521675A5 JP2014521675A5 JP2014523289A JP2014523289A JP2014521675A5 JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5 JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- biotinylated
- group
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 5
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 2
- 229960000060 monoclonal antibodies Drugs 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 230000002685 pulmonary Effects 0.000 claims 2
- 239000012217 radiopharmaceutical Substances 0.000 claims 2
- 230000002799 radiopharmaceutical Effects 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 claims 1
- 102100019896 CFTR Human genes 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 102000007193 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 1
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 230000002494 anti-cea Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Claims (14)
- 吸入による肺前処置剤として使用される、酸化型アビジンを含む医薬組成物。
- 肺の全体を前処置するための、請求項1に記載の医薬組成物。
- 前記吸入ステップの後にビオチン化治療剤を投与する、請求項1または2に記載の医薬組成物。
- 前記ビオチン化治療剤が、放射性医薬品、モノクローナル抗体、サイトカイン、ケモカイン、酵素、化学療法剤、ウイルスまたはプラスミドベクターおよび細胞から成る群から選択される、請求項3に記載の医薬組成物。
- 前記モノクローナル抗体は、抗EGFR、抗CEA、抗MUC1、抗EpCAM、抗cMET、抗CTL4、抗TNF、抗Tweak、抗IL−17、抗IL−23、抗IL−6、抗IL−1、抗TNF、および抗Tweakモノクローナル抗体から成る群から選択されるモノクローナル抗体のビオチン化誘導体である、請求項4に記載の医薬組成物。
- 前記ビオチン化サイトカインは、TNF、Tweak、TRAIL、γインターフェロン、G−CSF、GM−CSF、IL−2、およびIL−12から成る群から選択されるサイトカインのビオチン化付加物である、請求項4に記載の医薬組成物。
- 前記ビオチン化ケモカインがCXCおよびCCケモカインファミリーから成る群から選択されるケモカインのビオチン化付加物である、請求項4に記載の医薬組成物。
- 前記ビオチン化酵素が、嚢胞性線維症膜コンダクタンス制御因子タンパク質である、請求項4に記載の医薬組成物。
- 前記ビオチン化放射性医薬品が52Fe,52mMn,55Co,64Cu,67Cu,67Ga,68Ga,99mTc,111In,123I,125I,131I,32P,47Sc,90Y,109Pd,111Ag,149Pm,186Re,188Re,211At,212Pb,212Biおよび177Luを含む群から選択される放射性同位体で標識されたビオチン−DOTAである、請求項4に記載の医薬組成物。
- a)酸性pHの無菌緩衝液と、
任意で
b)マンニトール、グリセロール、グルコース、ラクトース、トレハロース、スクロース、プロピレングリコール、ソルビトール、キシリトール、ポリエチレングリコール、エタノールおよびイソプロパノールを含む群から選択される非イオン性物質と、
を含む、吸入するための、請求項1または2に記載の医薬品組成物。 - 凍結乾燥される請求項10に記載の吸入するための医薬品組成物。
- 請求項10または11に記載の医薬品組成物を含むキット。
- 請求項10に記載の医薬品組成物とネブライザーとを含むキット。
- COPD、喘息、肺胞隔炎、および嚢胞性線維症およびα−1−アンチトリプシン欠乏症を含む群から選択される肺癌疾患、肺炎症疾患の治療に使用される請求項10または11に記載の医薬品組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11006338.5 | 2011-08-02 | ||
EP11006338 | 2011-08-02 | ||
PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014521675A JP2014521675A (ja) | 2014-08-28 |
JP2014521675A5 true JP2014521675A5 (ja) | 2015-08-27 |
JP6019118B2 JP6019118B2 (ja) | 2016-11-02 |
Family
ID=46581966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014523289A Active JP6019118B2 (ja) | 2011-08-02 | 2012-07-25 | 吸入に適した酸化型アビジンの医薬品組成物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9872831B2 (ja) |
EP (1) | EP2739314B1 (ja) |
JP (1) | JP6019118B2 (ja) |
KR (1) | KR101966630B1 (ja) |
CN (1) | CN103717239B (ja) |
AU (1) | AU2012292229B2 (ja) |
BR (1) | BR112014002593B1 (ja) |
CA (1) | CA2842276C (ja) |
DK (1) | DK2739314T3 (ja) |
EA (1) | EA026453B1 (ja) |
ES (1) | ES2729549T3 (ja) |
IL (1) | IL230597A0 (ja) |
MX (1) | MX355177B (ja) |
PL (1) | PL2739314T3 (ja) |
PT (1) | PT2739314T (ja) |
UA (1) | UA114482C2 (ja) |
WO (1) | WO2013017494A1 (ja) |
ZA (1) | ZA201401921B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014107566A1 (en) | 2013-01-04 | 2014-07-10 | Massachusetts Institute Of Technology | Surface binding of nanoparticle based drug delivery to tissue |
WO2017201436A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Miami | Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
WO1995003034A1 (en) | 1993-07-19 | 1995-02-02 | Amgen Inc. | Stabilization of aerosolized proteins |
IL131445A0 (en) * | 1997-02-20 | 2001-01-28 | David S Dime | Site-specific drug delivery |
US7112341B1 (en) * | 1999-04-13 | 2006-09-26 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
AU2005315337B2 (en) * | 2004-12-17 | 2012-07-05 | Cipla Limited | Pharmaceutical compounds and compositions |
GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
SG183076A1 (en) * | 2007-08-02 | 2012-08-30 | Sigma Tau Ind Farmaceuti | Oxidized avidin with high residency time in the treated tissues |
EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt active IP Right Grant
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko active IP Right Grant
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en active Active
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en active Application Filing
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10550118B2 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
HRP20210650T1 (hr) | Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela | |
ES2892923T3 (es) | Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias | |
KR102568333B1 (ko) | Jak 저해제 화합물을 사용하는 치료 방법 | |
JP4598517B2 (ja) | 安定化した抗rsv抗体液体製剤 | |
JP2012034692A5 (ja) | ||
JP2011173911A5 (ja) | ||
JP2017081972A5 (ja) | ||
US11713315B2 (en) | 5 to 7 membered heterocyclic amides as JAK inhibitors | |
JP2021155454A5 (ja) | ||
Puljic et al. | Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF | |
HRP20151024T1 (hr) | Polipeptidi, varijabilne domene protutijela i antagonisti | |
JP2009521909A5 (ja) | ||
JP2018009002A5 (ja) | ||
Kimizuka et al. | Roles of interleukin-17 in an experimental Legionella pneumophila pneumonia model | |
JP2014521675A5 (ja) | ||
JP2017080507A5 (ja) | ||
JP2011530536A5 (ja) | ||
JP2021504321A5 (ja) | ||
JP2016508143A5 (ja) | ||
CN104231080A (zh) | 全人源抗人白介素17a单链抗体 | |
Thipphawong | Inhaled cytokines and cytokine antagonists | |
Jiang et al. | Interleukin-17A plays a key role in pulmonary fibrosis following Propionibacterium acnes–induced sarcoidosis-like inflammation | |
WO2015049633A1 (es) | FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. | |
Widowati et al. | Potential of human Wharton’s jelly mesenchymal stem cells (hWJMSCs) secretome for COVID-19 adjuvant therapy candidate |